Sunday, January 4, 2015

Top 5 Information Technology Companies To Watch For 2014

SAN FRANCISCO -- Now that Amazon.com has shown off its flying drones and Google has acquired robots that are faster and stronger than any human, my holiday wish for the technology industry this year is a little more loyalty toward their own customers.

The products made by software and hardware companies have the power to change human lives more than any other industry, save perhaps health care.

That's helped make the tech economy a large and growing part of the overall U.S. economy.

The tech sector enjoyed the widest operating profit margin of any sector within the S&P 500 Index in the third quarter, at roughly 16%.

Information technology consistently earns more operating income than any other U.S. industry, save for financial services, and last year accounted for 23% of corporate profits.

Top 10 Undervalued Companies To Invest In 2015: JinkoSolar Holding Company Limited(JKS)

JinkoSolar Holding Co., Ltd., together with its subsidiaries, engages in the manufacture and sale of solar power products in China and internationally. The company provides solar modules, silicon wafers and ingots, and solar cells, as well as processing services, including silicon wafer tolling services. It sells its products under the JinkoSolar brand name. The company?s customers include distributors, project developers, and system integrators. It trades its products under short-term contracts and by spot market sales. The company also produces accessory materials for solar power products, such as solar aluminum frame, solar junction box, aluminum materials windows, and other metal component parts. JinkoSolar Holding Co., Ltd. was founded in 2006 and is based in Shangrao, the People?s Republic of China.

Advisors' Opinion:
  • [By Zacks]

    On Dec 17, Zacks Investment Research upgraded JinkoSolar Holding Co., Ltd. (NYSE: JKS) to a Zacks Rank #1 (Strong Buy).

    Why the Upgrade?

  • [By Rick Munarriz]

    Friday
    The market is typically quiet on Friday, but don't tell that to JinkoSolar (NYSE: JKS  ) . The vertically integrated solar-power products maker closes out the trading week with its latest quarterly results.

  • [By Paul Ausick]

    Provided that the Chinese government either encourages or permits consolidation, any of these three could be an acquirer. The likeliest target, of course, is SunTech Power Holdings Co. Ltd. (NYSE: STP), which is reorganizing and which the government has already seemed to give up on. Other possible targets include ReneSola Ltd. (NYSE: SOL) and JinkoSolar Holding Co. Ltd. (NYSE: JKS).

  • [By Monica Gerson]

    JinkoSolar Holding Co (NYSE: JKS) is projected to report its Q2 earnings at $0.76 per share on revenue of $391.55 million.

    Urban Outfitters (NASDAQ: URBN) is expected to post its Q2 earnings at $0.49 per share on revenue of $806.99 million.

Top 5 Information Technology Companies To Watch For 2014: Johnson & Johnson(JNJ)

Johnson & Johnson engages in the research and development, manufacture, and sale of various products in the health care field worldwide. The company operates in three segments: Consumer, Pharmaceutical, and Medical Devices and Diagnostics. The Consumer segment provides products used in baby care, skin care, oral care, wound care, and women?s health care fields, as well as nutritional, over-the-counter pharmaceutical products, and wellness and prevention platforms under the brands of JOHNSON?S, AVEENO, CLEAN & CLEAR, JOHNSON?S Adult, NEUTROGENA, RoC, LUBRIDERM, DABAO, LISTERINE, REACH, BAND-AID, CAREFREE, STAYFREE, SPLENDA, TYLENOL, SUDAFED, ZYRTEC, MOTRIN IB, and PEPCID AC. The Pharmaceutical segment offers products in various therapeutic areas, such as anti-infective, antipsychotic, contraceptive, dermatology, gastrointestinal, hematology, immunology, neurology, oncology, pain management, and virology. Its principal products include REMICADE for the treatment of immune me diated inflammatory diseases; STELARA for the treatment of moderate to severe plaque psoriasis; SIMPONI, a treatment for adults with moderate to severe rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis; VELCADE for the treatment of multiple myeloma; PREZISTA and INTELENCE for treating HIV/AIDS patients; NUCYNTA for moderate to severe acute pain; INVEGA SUSTENNAtm for the acute and maintenance treatment of schizophrenia in adults; RISPERDAL CONSTA for the management of bipolar I disorder and schizophrenia; and PROCRIT to stimulate red blood cell production. The Medical Devices and Diagnostics segment primarily offers circulatory disease management products; orthopaedic joint reconstruction, spinal care, and sports medicine products; surgical care, aesthetics, and women?s health products; blood glucose monitoring and insulin delivery products; professional diagnostic products; and disposable contact lenses. The company was founded in 1886 and is based in Ne w Brunswick, New Jersey.

Advisors' Opinion:
  • [By Dan Carroll]

    Outside the financial sector, Johnson & Johnson (NYSE: JNJ  ) is pulling back following yesterday's earnings release, down 0.3%. Despite the stock's drop, J&J posted a generally positive quarter that saw adjusted earnings per share beat out Wall Street estimates by $0.09. The company's sale of its stake in drug producer Elan greatly boosted its quarter, but J&J's pharmaceutical side posted a welcome 12% gain in sales.

  • [By Sean Williams]

    Per a Johnson & Johnson (NYSE: JNJ  ) second-quarter conference call slide focusing on drugs launched since 2009, Pfizer only ranked sixth among the largest pharmaceutical companies based in the�U.S., Europe, and Japan in terms of cumulative sales of new drugs, with $4.8 billion. By comparison, privately held Boehringer-Ingelheim, Bristol-Myers Squibb, Gilead Sciences, and Novartis�all surpassed Pfizer, with Johnson & Johnson more than doubling Pfizer's cumulative new drug sales since 2009.�

Top 5 Information Technology Companies To Watch For 2014: GNC Acquisition Holdings Inc. (GNC)

GNC Holdings, Inc. operates as a specialty retailer of health and wellness products. It operates through three segments: Retail, Franchise, and Manufacturing/Wholesale. The company�s products include vitamins, minerals, and herbal supplement products, as well as sports nutrition products, diet products, and other wellness products. It also manufactures its branded products for various third parties. The company sells its products under GNC proprietary brands, including Mega Men, Ultra Mega, Total Lean, Pro Performance, and Pro Performance AMP, as well as under third-party brands. As of March 31, 2013, it had approximately 8,200 locations, including 6,200 retail locations in the United States; and franchise operations in 55 countries. The company sells its products through company-owned domestic retail stores, domestic and international franchise activities, third-party contract manufacturing, e-commerce, and corporate partnerships. It also offers its products at GNC.com, LuckyVitamin.com, and drugstore.com. GNC Holdings, Inc. was founded in 1935 and is headquartered in Pittsburgh, Pennsylvania.

Advisors' Opinion:
  • [By Tess Stynes var popups = dojo.query(".socialByline .popC"); popups.forEach(fu]

    GNC Holdings Inc.(GNC) lowered its full-year guidance and reported disappointing first-quarter results. The nutritional-products retailer attributed a same-store sales decline to severe winter weather. Shares fell 10% to $39.25 premarket.

  • [By Jake L'Ecuyer]

    GNC Holdings (NYSE: GNC) was down, falling 14.64 percent to $44.72 after the company reported weaker-than-expected Q4 results and issued downbeat FY14 guidance. Goldman Sachs downgraded the stock from Buy to Neutral and cut the price target from $72.00 to $54.00.

  • [By WWW.DAILYFINANCE.COM]

    kurhan/Shutterstock The maker of a line of diet supplements sold at the nation's largest pharmacies with the false promise that the pills would magically make users slender (they didn't) was banned -- at least, for now -- from selling weight loss products under a just-finalized agreement, the Federal Trade Commission said on Friday. HealthyLife Sciences and its principal sold Healthe Trim supplements with the claim you could "get high school skinny." Apparently, it only worked as advertised if its users had never gained weight after graduation. John Matthew Dwyer III (aka Matthew Dyer), the co-founder of the Atlanta-based company, agreed to stay out of the weight-loss industry under the terms of the settlement of deceptive advertising charges. Dwyer claimed the pills had ingredients that combined to burn fat, speed up the metabolism and suppress appetite. No Penalty, No Restitution The FTC said the company took in about $76 million between 2009 and 2013. Healthe Trim supplements were sold at CVS (CVS), Walgreens (WAG) and at GNC (GNC) stores. It cost consumers who bought into the spiel $50 to $65 for a month's supply, the FTC said. The key to the sales were customer testimonials featuring claims that, for example, using the pills helped one user to drop 54 pounds and go from a size 12 dress to a size 2. "Losing weight is rarely easy, and it would be a miracle if a pill made it so," Jessica Rich, director of the FTC's Bureau of Consumer Protection, said in a statement. "Consumers should be skeptical when a product like this one claims to make weight loss easy." The company itself (if it continues to operate without Dwyer) is barred from making a host of what the FTC describes as "scientifically infeasible" claims about its supplements. And it can no longer make any weight-loss-related claims at all about them until it has in hand two legitimate, scientifically rigorous human clinical-trial studies to support its statements. Unlike many settlements of this

Top 5 Information Technology Companies To Watch For 2014: Invesco Mortgage Capital Inc (IVR)

Invesco Mortgage Capital Inc., incorporated in June 2008, is a real estate investment trust (REIT). The Company is primarily focused on investing in, financing and managing residential and commercial mortgage-backed securities and mortgage loans, which it collectively refers to as its target assets. The Company�� target assets consist of residential mortgage-backed securities (RMBS) for which the United States Government agency, such as the Government National Mortgage Association (Ginnie Mae) or a federally chartered corporation, such as the Federal National Mortgage Association (Fannie Mae) or the Federal Home Loan Mortgage Corporation (Freddie Mac) guarantees payments of principal and interest on the securities. It refers to these securities as Agency RMBS. Its Agency RMBS investments include mortgage pass-through securities and may include collateralized mortgage obligations (CMOs). It also invests in RMBS that are not issued or guaranteed by the United States Government agency (non-Agency RMBS), commercial mortgage-backed securities (CMBS) and residential and commercial mortgage loans.

The Company finances its Agency RMBS, non-Agency RMBS and CMBS investments through short-term borrowings structured as repurchase agreements. The Company�� manager is Invesco Advisors Inc. The Company also finances its investments in certain non-Agency RMBS, CMBS and residential and commercial mortgage loans by contributing capital to the Invesco Mortgage Recovery Feeder Fund (Invesco IMRF Fund) that invests in public-private investment funds (PPIF) managed by the Company�� manager. The Company's manager is a wholly owned subsidiary of Invesco Ltd.

Advisors' Opinion:
  • [By Monica Wolfe]

    Invesco Mortgage Capital (IVR)

    President and CEO of Invesco Richard King reported a rather notable insider buy on Aug. 5. The CEO purchased 6,500 shares of company stock at an average price of $15.41 per share. This purchase cost King a total of $100,165. Since this buy, the share price has increased a minor 0.13%. King now holds on to at least 56,545 shares of Invesco Mortgage stock.

No comments:

Post a Comment